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Abstract
Delirium following solid organ transplant is a very common complication. 
Post-operative delirium has been shown to be associated with longer length of stays, 
increased post-operative complications, increased readmission rates, higher costs, 
and increased mortality. Therefore, every healthcare provider who is involved in 
the care of transplant recipients should be well educated in the importance of early 
diagnosis of delirium, treatment of potential contributing factors, and optimizing 
management. Routine delirium screening to allow prompt diagnosis and workup is 
paramount to the care of post-operative transplant patients. Identifying high risk 
individuals for pre-operative rehabilitation to help decrease post-operative delirium 
rates, as well as focusing on functional and cognitive recovery following delirium 
are important preventative and rehabilitation efforts to optimize outcomes for 
transplant patients. This chapter will highlight a proactive approach to delirium 
prevention and management in the transplant population.
Keywords: delirium, outcomes, complications, altered mental status,  
solid organ transplant, cognitive impairment
1. Introduction
Delirium following transplantation is a wide reaching problem that has a 
significant effect on recovery time, functional outcomes, and has a profound 
economic impact on the healthcare system. Delirium is now being recognized as 
a major driver of poor health care related outcomes. Post-operative delirium has 
been shown to be associated with longer length of stays, increased post-operative 
complications, increased readmission rates, higher costs, longer periods of mechan-
ical ventilation, prolonged cognitive impairment and increased mortality [1, 2]. 
With this in mind, early diagnosis of delirium, treatment of potential contributing 
factors, and optimized management is paramount to improve post-transplant 
outcomes. This chapter will highlight a proactive approach to delirium management 
and prevention in the abdominal transplant population.
1.1 Definition
Delirium is defined as a condition highlighted by an acute disturbance in atten-
tion, awareness and cognition that is not explained by a preexisting neurocognitive 
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disorder. Delirium is characterized by reduced capacity to direct, focus, sustain, 
or shift attention, as well as reduced orientation to the environment [1, 3]. These 
symptoms must present acutely and fluctuate throughout the day. Importantly, the 
diagnosis of delirium identifies the constellation of symptoms representing altered 
brain function, but does not identify the etiology (Figure 1).
Delirium can be classified into three subtypes based on psychomotor behavior: 
hyperactive, hypoactive and mixed type delirium. Delirium is under diagnosed due 
to inconsistent screening, but also because delirium has varying and inconsistent 
presentations especially in patients suffering from hypoactive delirium. Hypoactive 
delirium is characterized by slowed mentation, lethargy, and decreased move-
ment, whereas hyperactive delirium is marked by agitated behavior, confusion 
and difficulty with re-orientation. Without consistent, evidence-based screening 
methods, hypoactive delirium is more likely to be overlooked compared to hyperac-
tive delirium. In addition, the different forms of delirium carry different prognosis. 
In a study of patients admitted to the intensive care unit after elective operations, 
patients that suffered from hypoactive delirium had an increased six-month mortal-
ity compared to patients with other subtypes of delirium (32 vs. 8.7%, P = 0.04) [4]. 
Therefore, it is important understand the various forms of delirium and the clinical 
scenarios in which it can present to allow timely diagnosis and management.
1.2 Prevalence
The prevalence of delirium is highly variable based on the population being 
evaluated. It has been reported to occur in 16–89% of hospitalized patients, and up 
to 50% of post-operative patients [5, 6]. Delirium is the most common manifesta-
tion of acute brain dysfunction during critical illness. Reports note that delirium 
affects 50–75% of patients who receive medical ventilation in the intensive care unit 
[5]. The prevalence in the transplant population has been reported to range from 12 
to 47% of patients [7]. Patients undergoing liver transplant have a higher prevalence 
of developing delirium than other abdominal transplant recipients occurring in 
Figure 1. 
Clinical symptomatology associated with delirium.
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approximately 45% of the liver recipients [8]. In a recent report by Haugen et al. 
only 0.8% of kidneys transplant recipients developed delirium [9]. The difference 
in prevalence of delirium in abdominal transplant recipients needs to be considered 
when developing preventive strategies to provide targeted interventions on high-
risk populations.
1.3 Pathophysiology
The pathophysiology associated with delirium development is multifactorial and 
is associated with complex interactions between systemic and cerebral physiology. 
The precise mechanisms are still being investigated, however many hypotheses 
exist for the underlying precipitating factor(s) that lead to delirium development. 
Examples of different hypotheses include inflammatory-mediated neuronal injury, 
altered cerebral perfusion, increased permeability of the blood brain barrier from 
endothelial dysfunction, and altered neurotransmitter balance [10]. In addition, 
the anatomic changes associated with advanced age including cerebral atrophy and 
changes in white matter density have been considered to contribute to the underlying 
mechanism of delirium, and also represent risk factors for delirium development [11].
Delirium pathophysiology is also believed to be associated with the systemic 
inflammatory cascade that occurs as a result of the stress response following an 
acute event, trauma or surgical intervention. The release of inflammatory media-
tors and cytokines (cortisol, c-reactive protein, interleukin-6, interleukin-8, etc.) 
following surgery likely play a significant role in the pathophysiologic link between 
surgery and delirium development [10]. Microglial cells have an intimate involve-
ment in mediating the cerebral inflammatory response that occurs as a result of the 
systemic inflammatory response following surgery. The microglial cells up regulate 
the production of pro-inflammatory cytokines, which lead to disturbances in 
cognitive function and alterations in cerebral activity. In addition, over-activation 
of microglial cells can lead to neuronal apoptosis [10]. Thus, understanding the 
cellular and molecular pathways associated with microglial physiology may provide 
opportunities for intervention and targeted therapy for delirium treatment.
Endothelial cells serve as integral components of a competent blood brain 
barrier; however, in the setting of stress, surgery, inflammation, etc., endothelial 
function is altered leading to a reduction in the integrity of the highly selective 
blood brain barrier. This increases the risk of cerebral dysfunction and delirium 
development. Hughes et al. assessed biomarkers associated with the integrity of 
the blood brain barrier and endothelial dysfunction, and found that elevations 
in S1008, E-selectin and plasminogen activator-1 were associated with delirium 
in critical illness [12]. Endothelial dysfunction also up-regulates the coagulation 
pathways leading to microvascular thrombi formation, which consequently alters 
cerebral blood flow further leading to cerebral dysfunction.
Delirium is also linked to neurotransmitter dysfunction and deregulation. 
Acetylcholine is an important modulator of the systemic inflammatory response 
by decreasing the number of inflammatory cytokines. Critical illness and surgical 
stress create a physiologic environment that leads to depletion of acetylcholine 
stores and availability. A lack of acetylcholine receptor activation on the surface of 
microglial cells causes a lack of inhibition and leads to hyperactivation of microglial 
cells [10]. The acetylcholine association with delirium explains the pathophysiology 
involved with the increased risk of delirium in patients receiving anti-cholinergic 
medications. These medications exacerbate the depleted stores of acetylcholine 
that is associated with stress and post-surgical states. Hence, an important compo-
nent of post-operative delirium prevention is to avoid the use of anti-cholinergic 
medications.
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Additional neurotransmitter imbalances associated with the development 
of delirium include dopamine, serotonin, and norepinephrine [1, 10]. Elevated 
levels of dopamine and norepinephrine are associated with hyperactive delirium 
[13]. Increased norepinephrine levels contribute to agitation, impaired attention 
and cerebral dysfunction. Increased serotonin levels are also linked to cerebral 
dysfunction and increased risk of delirium. Gamma-aminobutyric acid (GABA) 
is the primary neurotransmitter associated with inhibitory pathways in the brain. 
Dysregulation of GABA is associated with delirium. The administration of drugs 
that are mechanistically involved in activation or inhibition of the GABA receptor 
or altering levels of other important neurotransmitters are associated with delirium, 
and efforts should be made to minimize patient exposure to these medications, such 
as benzodiazepines [13].
Overall, the pathophysiology linked to delirium is complex and incompletely 
understood. Importantly, delirium is the clinical manifestation that results from the 
interaction of multiple different dysfunctional systemic and cerebral physiologic path-
ways. As the understanding of the pathophysiology that leads to delirium improves, 
targeted pharmacologic agents can be developed and tested in clinical scenarios.
2. Diagnosis
2.1 Risk factors
Delirium is a very common complication following transplantation. It is impor-
tant to have an appreciation for the risk factors linked to delirium development in 
order to optimize preventive measures and allow for early diagnosis. Advancing age 
and baseline cognitive impairment are the most commonly described risk factors 
for developing delirium [14, 15]. Certain medical conditions can also predispose 
patients to delirium. Sleep apnea, heart failure, diabetes and frailty have been 
shown to increase the risk of developing delirium [16]. Patients with lower cogni-
tive and functional reserve likely have a reduced ability to maintain normal brain 
function in the setting of an acute stress event, such as surgery, sepsis or trauma. 
It is important to identify these risk factors that are present pre-operatively to help 
reduce the prevalence of delirium after transplant.
If cognitive dysfunction can predispose patients to delirium, an important 
question to answer when discussing delirium in transplant recipients is if surgery 
and/or anesthesia is an independent risk factor for post-operative cognitive defects 
(i.e. an unmodifiable risk factor for transplant recipients). A multicenter, prospec-
tive cohort study involving patients with surgical and nonsurgical critical illness 
was performed to evaluate if surgery and anesthesia was a risk factor for delirium. 
This study reported that surgery/anesthesia was not a risk factor for impairment of 
long-term global cognitive function or executive function after major non-cardiac 
surgery. In addition, increasing the level of exposure as measured by number of sur-
geries and duration of anesthesia was not associated with worse global cognitive or 
executive function. Cognitive impairment was highly prevalent at 3 and 12 months 
after hospital discharge in patients who suffered delirium. However, delirious 
patients who were exposed to general anesthesia and surgery suffered cognitive 
impairment at rates similar to those who did not undergo a surgical procedure. Post-
operative cognitive impairment was associated with pre-existing cognitive deficits 
and level of education [3]. Based on these data, surgery and anesthesia does not 
appear to be an independent risk factor for delirium development and emphasizes 
the need for patient- and disease-focused risk stratification as transplant patients 
have many disease-specific risk factors that increase the incidence of delirium.
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Risk factors for delirium in patients undergoing liver transplantation include 
a history of alcohol abuse, pre-operative hepatic encephalopathy, pre-operative 
renal replacement therapy, intra-operative red blood cell transfusion volume and 
increasing Acute Physiologic and Chronic Health Evaluation II (APACHE II) scores 
upon intensive care unit admission. A study by Wang et al. showed that risk fac-
tors associated with delirium in liver transplant patients in the intensive care unit 
included history of alcohol abuse (Odds ratio: 6.40), preoperative hepatic encepha-
lopathy (Odds ratio: 4.45), APACHE II score > 16 (Odds ratio: 1.73), and duration of 
endotracheal intubation for >5 days (Odds ratio: 1.81) [17]. Lescot et al. performed 
an observational study of liver transplant patients admitted to the intensive care unit 
after deceased donor transplant. Neither age nor etiology of cirrhosis was signifi-
cantly associated with delirium [18]. Furthermore, delirium was not significantly 
associated with Model for End Stage Liver Disease score or Child-Pugh score. The 
median number of intraoperative transfused packed red blood cell units in patients 
with delirium was more than double that of in patients without delirium (P = 0.001). 
The risk of developing delirium was greater in patients with pre-transplant encepha-
lopathy (P = 0.02) and in patients who underwent renal replacement therapy during 
the pretransplantation period (P < 0.01). In the logistic regression model, number of 
red blood cell transfusions, renal replacement therapy, and elevated APACHE scores 
were associated with increased risk of delirium. Interestingly, if a patient required 
renal replacement therapy, they had 13-fold greater odds of becoming delirious [18].
Haugen et al. evaluated 893 kidney transplant recipients and examined risk 
factors for developing postoperative delirium [9]. Risk factors in patients with end 
stage renal disease undergoing kidney transplantation include age greater than 65 
(Odds ratio: 2.65, P = 0.004), frail patients (Odds ratio: 2.05, P = 0.04), and increas-
ing comorbidities (two or more on the Charlson Comorbidity Index) (Odds ratio: 
1.93 P = 0.05). In regards to delirium in pancreas transplant recipients, there are 
currently no organ specific factors detailed in the literature; however, the known 
risk factors for delirium associated with patients undergoing kidney transplantation 
can be theoretically applied to pancreas transplant recipients as these patients share 
similar demographics and disease processes.
Post-operative factors that contribute to delirium include inadequate pain 
control, need for mechanical ventilation, sedation levels, benzodiazepine use, poor 
sleep hygiene, electrolyte disturbances, and infections. Medication used to treat 
common post-operative symptoms such as nausea including prochlorperazine 
or phenergan are associated with delirium. Benzodiazepines are also strongly 
associated with a higher risk of delirium and should only be used in very select 
circumstances at reduced doses in young patients with chronic home benzodiaz-
epine use. Opioids increase delirium risk and should be used in moderation. Pain 
control should focus on multimodal treatment protocols with opioid sparing when 
applicable. Medications that alter the cholinergic neurotransmitter pathway, such as 
diphenhydramine, promethazine, tricyclic antidepressants or prochlorperazine are 
strongly associated with delirium development and should be avoided. In addition, 
immunosuppressive medications, such as calcineurin inhibitors and steroids, can be 
associated with mental status changes [19]. In transplant recipients at high risk for 
developing delirium or patients who have developed delirium, an important step in 
managing and optimizing these patients is to review the medication list to limit and 
discontinue any deliriogenic medication.
2.2 Screening
Early diagnosis of post-operative delirium is paramount for prompt manage-
ment and minimization of risk for improved speed of recovery. There are several 
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validated screening tools for assessing for the presence of delirium. The gold stan-
dard for diagnosis of delirium is a formal evaluation performed by a psychiatrist 
using The Diagnostic and Statistical Manual of Mental Disorders criteria; however, 
the application and feasibility of a formal psychiatric evaluation is not clinically 
practical [1]. More commonly used methods of delirium screening utilize nursing 
expertise for frequent and consistent bedside screening. The Richmond Agitation 
Sedation Scale (RASS) is a widely used screening tool to evaluate and communicate 
patients’ level of sedation and arousal [20]. With an appropriate level of conscious-
ness, there are many validated tools for delirium screening. Importantly, a patient 
must be arousable to voice (i.e. RASS score of −1) to be able to screen for delirium. 
The most commonly used tool for screening is the Confusion Assessment Method 
for Intensive Care Unit (CAM-ICU) [21]. The CAM-ICU (Figure 2) is an abbrevi-
ated version of the Confusion Assessment Method. The CAM-ICU tool screens for 
acute changes in mental status, inattention, disorganized thinking and altered level 
of consciousness in a condensed approach ideal for a fast paced clinical setting. The 
CAM-intensive care unit screening tool requires less than 2 min to complete and 
in addition to being rapidly applied, has been shown to be 93% sensitive and 98% 
specific for diagnosing delirium [21].
Other screening tools include the Nursing Delirium Symptom Checklist 
(NuDESC) [22], Confusion Assessment method (CAM) [23] and the Intensive Care 
Delirium Screening Checklist (ICDSC) [24]. The multiple, validated tools available 
speaks to the importance for using a tool of any type to achieve consistent screen-
ing. More important than which tool to use is having a program in place for regular, 
routine, and consistent screening. If delirium is not screened for using a validated 
screening tool, delirium may be missed up to 75% of the time [25–28], especially 
in the setting of hypoactive delirium. Given the fluctuating course of critically 
Figure 2. 
Delirium screening tool and flowchart outlining the confusion assessment method for the intensive care unit [2].
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ill patients and delirium, it is important that screening be performed in a serial, 
repeatable and consistent manner to achieve timely diagnosis and prevent under 
diagnosis. Routine implementation of validated screening tools allows for rapid and 
dependable evaluation and subsequent work up to identify potential underlying 
etiologies and ultimately directed delirium management.
2.3 Delirium work up
Following a positive screening evaluation for delirium, working through 
a differential diagnosis to identify treatable underlying causes is essential. In 
the transplant population in the setting of immunosuppression, infection is 
an extremely important diagnosis to consider and rule out in a timely manner. 
Immunosuppressed patients do not have a robust systemic inflammatory response 
as compared to non-immunosuppressed, post-operative patients, so infections pres-
ent in a more discreet and subtle manner, often with mental status changes as the 
only clinical symptomatology. In a patient with new onset delirium, initial work up 
should include a comprehensive laboratory evaluation including a complete blood 
count, comprehensive metabolic panel, liver function tests, lipase and amylase. In 
the post-transplant recipient where renal dysfunction and electrolyte fluctuations 
are common, a basic metabolic panel should also be obtained to ensure that uremia 
or an underlying electrolyte disturbance is not present. Hormone dysregulation 
should also be considered as a cause of delirium with laboratory evaluation of 
thyroid function and the pituitary–adrenal axis. The patient’s medication list should 
also be reviewed to ensure that medication toxicity is not contributing or exacerbat-
ing the mental status changes. However, in the immunosuppressed, post-operative 
transplant recipient with clinical decompensation highlighted by new onset mental 
status changes, sepsis needs to be at the top of the differential diagnosis.
Mental status changes are often the initial presenting symptom of an underlying 
infection or sepsis in the transplant population. Blood cultures, urine cultures, and 
a chest x-ray should be obtained to rule out bacteremia, urinary tract infection or 
pneumonia, respectively. In addition, based on the operative details and time since 
surgery, cross sectional axial imaging should be considered to rule out a deep space 
infection or other possible surgical complications. Importantly, early initiation of 
broad-spectrum antibiotics is strongly recommended if there is any concern that an 
underlying infection is contributing to the mental status changes.
If surgical drains are present, evaluating the character of the abdominal fluid 
is important to rule out intra-abdominal pathology. Organ specific evaluation of 
surgical drains is an important step in evaluating for potential infectious sources. 
In the setting of liver transplant, drains should be evaluated for elevated bilirubin 
to rule out a biloma and anastomotic biliary complication. In pancreas recipients, 
drain amylase and bilirubin should be obtained to evaluate for a pancreatic paren-
chyma leak and/or an enteric anastomotic leak. If clinically applicable in kidney 
transplant recipients, drain fluid should be checked for creatinine to evaluate for a 
possible urine leak. Drain fluid studies should be correlated with high resolution, 
axial imaging to further define the anatomic location of potential fluid collections 
to determine if percutaneous drainage or open drainage is needed.
Furthermore, the work up should include placing the patient on a pulse oxim-
eter to obtain an oxygen saturation and obtain an arterial blood gas to ensure that 
hypoxia or hypercarbia is not causing or contributing to the mental status changes.
Myocardial infarctions and cerebral vascular events can also present with 
delirium. An electrocardiography, troponins and a possible echocardiography 
should be obtained if there is a concern for a cardiac event. If there is clinical 
suspicion for a stroke based on neurologic exam, a non-contrast and subsequently 
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contrasted cerebral, cross sectional imaging should be obtained. In addition, an 
electroencephalography should be performed if there is clinical concern for seizure 
activity or postictal metal status changes.
Mental status changes in the transplant recipient can be caused by multiple con-
tributing factors, and a systematic and thoughtful work up is paramount for rapid 
initiation of treatment. However, the work up for delirium is often negative for any 
treatable, underlying medical condition. Once all potential medical conditions that can 
contribute to delirium are evaluated and eliminated as the diagnosis, the focus should 
shift to optimizing the environment for delirium resolution and cognitive recovery.
3. Prevention
3.1 Pre-operative prevention
Surgery can result in accelerated cognitive and functional decline, and this cog-
nitive impairment after surgery has been associated with increased mortality and 
disability with deficits in activities of daily living occurring in up to 50% of patients 
even 12 months after major surgery [29–34]. Patients with a higher physical and 
cognitive reserve have a protective effect on reducing the risk of developing delir-
ium [35, 36]. Therapeutic approaches for improving cognitive reserve may present 
opportunities for reducing cognitive impairment after acute stressors, particularly 
in situations with time available for prehabilitation. An area that is understudied in 
the transplant population is whether building patients’ mental and physical reserve 
through a prescribed program of cognitive and physical exercise, as well as nutri-
tional optimization can improve long term outcomes. Prehabilitation efforts before 
surgery thus far have focused on preemptive physical therapy to improve post-sur-
gical functional outcomes. Multiple studies have demonstrated that physical train-
ing prior to surgery to build physical reserve can improve functional outcomes after 
major surgery [37–39]. No work, however, has been done to attenuate the cognitive 
decline by “exercising the brain” before the physiologic insult that is commonly seen 
in chronic disease and surgical intervention such as transplantation.
By targeting high-risk individuals, such as those who are frail, encephalopathic, 
uremic, have a history of alcohol abuse, are of advanced age, and have higher Model 
for End Stage Liver Disease scores, cognitive reserve could be improved. There 
are interventions focused on cognitive remediation/rehabilitation that are being 
studied, which potentially hold promise for improving long-term brain functioning 
in transplant recipients. Among them, Cognitive Retraining is a novel therapeutic 
approach. Conceptually, Cognitive Retraining applies well-understood techniques 
derived from brain plasticity research [40]. The learning theory facilitates improve-
ment in information processing, attention control, aspects of memory, and execu-
tive functioning. Research has been performed evaluating the effectiveness of 
computer-based cognitive remediation on various aspects of neuropsychological 
functioning including memory, attention, processing speed, and others [41–43]. 
Based on prior experience with a wide variety of patient populations, there is a high 
likelihood of fostering improvement in patient outcomes in transplant recipients if 
applied to high risk individuals at risk for cognitive impairment and delirium during 
their postoperative recovery.
3.2 Intra-operative management
It is extremely important for anesthesia providers to practice delirium preventive 
strategies. There are operative factors that need to be considered that are associated 
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with increased delirium, which include the use of anticholinergic medications, 
electrolyte disturbances (specifically sodium fluctuations), and the amount of 
red blood cell transfusions. Efforts to decrease the prevalence of postoperative 
delirium should focus on limiting patient exposure to deliriogenic medications 
intra-operatively. The choice of anesthetic does not increase the risk of delirium 
as there is no conclusive evidence that propofol versus an inhaled based anesthetic 
changes the incidence of post-operative delirium [44, 45]. However, the level/depth 
of sedation provided during the operation is associated with delirium development, 
and therefore instruments such as intra-operative electroencephalography or brain 
activity monitors have been suggested to mitigate excessive levels of anesthesia 
helping with delirium prevention post-operatively. [46]. Close attention to elec-
trolyte concentrations and fluctuations intraoperatively is also important. This is 
especially critical in patients with chronic hyponatremia, and in operations that 
involve large volume crystalloid resuscitation or excessive blood loss with associated 
blood product administration. Detailed pre-operative planning to minimize large 
fluctuations and optimize electrolyte disturbances should be performed with the 
surgical and anesthesia teams in high-risk individuals. Intra-operative management 
is an important part of the continuum of care for the transplant patient in delirium 
prevention.
3.3 Post-operative prevention
3.3.1 Pharmacologic prophylaxis
Studies evaluating whether pharmacologic prophylaxis reduced the incidence 
of delirium have shown mixed results. A large double blind, placebo controlled 
trial studied prophylactic dexmedetomidine infusion upon arrival to the intensive 
care unit. The intervention group demonstrated a significant reduction in the 
incidence of delirium in non-cardiac post-operative elderly patients compared 
to the control group [47]. Treatment with dexmedetomidine in elderly patients 
admitted to the intensive care unit after non-cardiac surgery reduced the inci-
dence of delirium from 23 to 9%. Dexmedetomidine also reduced the amount of 
sedative drugs including narcotics administered. The authors suggested that the 
delirium reduction seen in the trial could be contributed to a possible neuropro-
tective effect of dexmedetomidine and/or a reduction in sedation medications. 
Wide spread clinical use of dexmedetomidine is limited by the fact that it must 
be used in in an intensive care setting being administered intravenously, as well 
as the possible cardiopulmonary side effect profile causing respiratory depres-
sion, hypotension and bradycardia. However, these results are encouraging for 
the use of dexmedetomidine in the prophylactic setting in patients at high risk for 
delirium.
There are no data on the use dexmedetomidine use in patients admitted to the 
intensive care unit following abdominal transplant, but this approach could be 
applicable to liver transplant patients who remain intubated at the time of intensive 
care unit admission to be used as sedation instead of fentanyl or propofol. Further 
work will need to be done to delineate a clinical benefit for routine use of dexme-
detomidine in postoperative transplant patients.
A recent randomized controlled trial-The Haloperidol Effectiveness in ICU 
Delirium (HOPE-ICU) study-showed no difference in days alive and free of 
delirium between patients prophylactically treated with intravenous haloperidol 
(2.5 mg every 8 hours) or placebo [48]. At this time, the data are not conclusive to 
make a formal recommendation for routine pharmacologic prophylaxis for delirium 
prevention.
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3.3.2 Non-pharmacologic prevention
Implementing non-pharmacologic based prevention bundles for delirium 
reduction have resulted in improved rates of delirium. The clinical care bundles 
focus on reducing exposure to and mitigating delirium risk factors such as appro-
priate pain management, timely Foley catheter removal, re-orientation strategies, 
and reducing hearing and vision deficits. Implementation of these protocols has 
reduced delirium rates and total days of delirium in multiple studies [49–51]. There 
is a growing emphasis on a multimodal approach to pain control to reduce exposure 
to deliriogenic narcotic pain medication. Multimodal pain control emphasizes 
opioid reduction with the use of a combination of acetaminophen, non-steroidal 
anti-inflammatory medications, ketamine, gabapentin and/or regional anesthetic 
techniques where appropriate. A multi-disciplinary approach with anesthesia, pain 
specialists and the surgical team should be implemented to optimize post-operative 
pain control with narcotic avoidance/reduction protocols.
Combining evidence-based interventions that reduce delirium rates have 
been shown to be effective and the combination of different strategies can have 
additive beneficial effects on delirium prevention. The Awakening and Breathing 
Coordination, Delirium Monitoring/Management, and Early Mobility (ABCDE) 
bundle is the most described bundle in the literature (Figure 3). Initially published 
in 2011 [52], this bundle has proven to be an effective strategy in delirium preven-
tion. The ABCDE bundle is comprised of a number of interventions shown to 
improve outcomes in several well-designed clinical trials. The ABCDE bundle is an 
evidence-based, multicomponent management strategy aimed at reducing sedation 
exposure, duration of mechanical ventilation and hospital-acquired delirium and 
weakness. In comparison to standard practice including spontaneous breathing 
trials and spontaneous awakening trials (but no consistent delirium screening), 
the ABCDE bundle group experienced less delirium (48.7 vs. 62.3%, P = 0.02) and 
a lower percent of intensive care unit days spent delirious (33 vs. 50%, P = 0.002) 
[53]. The “AB“ component of the bundle focuses on expedited mechanical ventila-
tion liberation, and has been shown to decrease duration of medical ventilation, 
duration of coma and mortality [54, 55]. The “C” of the bundle is focused on 
avoiding over sedation and use of benzodiazepines, which has been shown in clini-
cal trials to decrease delirium and duration of mechanical ventilation [56–58]. The 
“D” of the bundle refers to regular delirium screening and monitoring. The “E” of 
the bundle highlights the need for early mobility, which has been shown to decrease 
duration of delirium, intensive care unit length of stay and mortality [59]. A recent 
prospective, cohort study evaluated the effects of the ABCDE bundle on delirium 
rates. After the bundle was implemented, the prevalence of delirium decreased 
significantly from 38 to 23% (P = 0.01). The number of days with delirium was also 
reduced from 3.8 to 1.72 days (P = <0.001) [60]. These data support a focused, clini-
cal care bundle approach to delirium prevention and prospective implementation in 
postoperative solid organ transplant recipients.
4. Treatment and management
4.1 Management
Most of the data exploring practice recommendations for delirium management 
is rooted in the critical care literature. Over the past two decades, significant shifts 
in practice paradigms have helped reduce the incidence of delirium in the intensive 
care unit. The major advancements in delirium management and prevention include 
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the level of sedation delivered while receiving mechanical ventilation. Daily awak-
ening trials where sedation is interrupted to evaluate the ability to liberate from 
mechanical ventilation coupled with spontaneous breathing trials has been shown 
in randomized controlled studies to reduce mechanical ventilation days as well as 
delirium incidence [54, 61].
In addition, the choice of medication for sedation has shifted from benzodi-
azepines to propofol or dexmedetomidine infusions. This management shift was 
based on randomized controlled studies evaluating delirium outcomes and rates 
in patients receiving dexmedetomidine versus lorazepam infusions for sedation. 
Longer duration of lorazepam exposure was significantly associated with increased 
rates of delirium [57]. This study of 106 critically ill patients found that the patients 
receiving dexmedetomidine had more delirium free days compared to the loraz-
epam group (7 vs. 3, P = 0.01). Not only does duration of benzodiazepine exposure 
increase the incidence of delirium, it has been shown that delirium risk increases 
with amount of lorazepam administered [62].
An unintended consequence of routine intensive care unit care is sleep disrup-
tion and interference with sleep quality. Fragmented sleep has been associated 
with delirium. A focus on promoting and maintaining adequate sleep hygiene is an 
important delirium preventive measure. Efforts to minimize overnight disruptions 
and promote normal circadian rhythms have been associated with lower odds of 
developing delirium. Non-pharmacologic measures should be implemented to aid 
in sleep quality improvement and maintenance of sleep hygiene such as exposure 
to natural light, activity/mobility during the day, reduction of nighttime noise, 
removal of nocturnal stimulation, and reductions in night time nursing disrup-
tions. A quality improvement project aimed at improving sleep by minimizing sleep 
A
E
D
C
B
Awake and Breathing Coordination
-Daily spontaneous awakening and breathing trials  
-Decreases duration of mechanical ventilation 
-Decreases mortality 
Choose light sedation 
 -Avoid benzodiazepines 
 -Consider dexamedetomidine 
 -Reduces delirium rates and mortality 
Delirium monitoring and management
 -Routine delirium screening  
 -Increases delirium detection
 -Focus on nonpharmocologic treatment  
Early mobility and exercise
 -Early physical therapy and occupation therapy      
 -Reduces delirium rates
 -Coordinate with periods of reduced sedation  
Figure 3. 
Overview of the ABCDE delirium prevention bundle.
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disruptions and promoting normal circadian rhythms using non-pharmacological 
sleep aids has been shown to decrease the incidence of delirium and improve daily 
delirium free status [63].
Early mobilization is also an important strategy for delirium prevention. A trial 
of early mobilization that randomized hemodynamically stable patients to daily 
sedation interruptions timed with physical and occupation therapy versus usual 
care without early mobilization therapy achieved a two-day reduction in delirium 
duration in the treatment arm (days with delirium: 2 vs. 4 days, P = 0.03) [59]. In 
addition, early mobilization in this study reduced the time in the intensive care 
unit with delirium (33% of patients in the intervention group were diagnosed with 
delirium vs. 57% of patients in the control group were diagnosed with delirium, 
P = 0.02), as well as time in the hospital with delirium (28% of patients in the 
intervention group were diagnosed with delirium vs. 41% of patients in the control 
group were diagnosed with delirium, P = 0.01). Therapy included passive range of 
motion, active range of motion, and activities of daily living training depending on 
the patients’ level of sedation and ability. In another recent randomized controlled 
trial of surgical critically ill patients, early goal-directed mobilization reduced the 
incidence of delirium and increased the number of delirium free days in the inten-
sive care unit when compared to usual care [64].
4.2 Pharmacologic treatment
Currently, there are no evidence-based guidelines regarding specific pharmaco-
logical agents for delirium treatment. The current first line agents used in the treat-
ment of hyperactive delirium are antipsychotic medications including haloperidol, 
olanzapine and quetiapine. Of note, neither antipsychotics nor dexmedetomidine 
have FDA approval for the treatment of delirium. In an international survey of 1521 
intensivists, 65% reported that they treat delirium in the intensive care unit with 
haloperidol and 53% reported that they treat delirium with atypical antipsychotic 
medications [65], but there is no evidence-based literature showing efficacy of 
these medications for delirium treatment and symptom resolution. Despite cur-
rent practice patterns, there are few data to support their definitive use in treating 
delirium.
A recent study evaluating the treatment of delirium with haloperidol (2.5–5 mg 
every 8 h) versus olanzapine (5 mg daily) showed no difference in length of 
delirium in 73 critically ill patients [66]. Furthermore, in a randomized, double 
blind, placebo-controlled trial, patients with acute respiratory failure or shock and 
hypoactive or hyperactive delirium were assigned to receive intravenous boluses of 
haloperidol (maximum dose, 20 mg daily), ziprasidone (maximum dose, 40 mg 
daily), or placebo [67]. The primary end point was the number of days alive with-
out delirium or coma during the 14-day intervention period. The use of haloperidol 
or ziprasidone, as compared with placebo, in patients with acute respiratory failure 
or shock and hypoactive or hyperactive delirium in the intensive care unit did not 
significantly alter the duration of delirium. This randomized, placebo-controlled 
trial of intravenous antipsychotic medications for the treatment of delirium in 
critically ill patients showed that pharmacologic treatment was no different than 
placebo [67].
Dexmedetomidine in delirium management has gained popularity over the past 
several years. A recent trial studied dexmedetomidine in mechanically ventilated 
patients who were unable to be weaned from mechanical ventilation due to hyperac-
tive delirium. This study, Dexmedetomidine to Lessen ICU Agitation trial, random-
ized patients to receive 7 days of intravenous dexmedetomidine (up to 1.5 μg/kg/h) or 
placebo. Patients treated with dexmedetomidine had fewer days requiring ventilator 
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support and had faster resolution of delirium symptoms (23 vs. 40 h, P = 0.01) [68]. 
Dexmedetomidine must be administered as an infusion, which means the drug can 
only be given to patients having critical care needs. Alternative oral alpha-2 agonists 
exist, including clonidine or guanfacine, which could facilitate therapy in non- inten-
sive care unit settings or during transition of care. However, these agents have not 
been rigorously studied in regards to delirium treatment and prevention as options for 
oral transition or alternatives to dexmedetomidine.
As strong evidence supporting the use of single pharmacological agents in 
delirium is lacking, preventive strategies and non-pharmacologic treatment 
bundles, such as the ABCDE bundle as discussed above, should be incorporated into 
delirium prevention and management algorithms.
4.3 Cognitive therapy following delirium
Cognitive and physical dysfunction is a common sequela for patients following 
a prolonged course of delirium. Recently, efforts have been made to minimize the 
long-term effects of delirium through exercises focused on orientation, memory, 
attention, and problem solving. A recent study implemented a graded cognitive 
therapy protocol with varying degrees of intensity guided by the patient’s RASS 
assessment immediately preceding the session [69]. Examples of the cognitive 
therapy performed in this study included matrix puzzles, noun list recall, paragraph 
recall, letter-number sequence, and pattern recognition. The authors showed that 
following discharge from the intensive care unit, combined cognitive and physical 
therapy was associated with improved executive functioning at the time of hos-
pital discharge [69]. These data suggest that once a patient is able to participate in 
therapy following delirium recovery, efforts should be made to incorporate cogni-
tive rehabilitation as an integral part of the recovery process to maximize functional 
outcomes.
Extending beyond inpatient rehabilitation, research has been conducted into 
performing cognitive rehabilitation following hospital discharge in patients who 
suffered from delirium [70]. In this study the rehabilitation program was provided 
over a 12-week period after discharge in each patient’s home and integrated both 
traditional “face-to-face” interventions as well as telephone and video-based 
interventions for cognitive, physical and functional rehabilitation. The cognitive 
training was based on the goal-management training (GMT) protocol, a focused 
and theoretically derived stepwise approach to the rehabilitation of executive func-
tion. The GMT sessions build on one another to increase the “dose” of rehabilitation 
delivered. These cognitive sessions resulted in improved scoring on tests evaluating 
executive functioning [70].
Based on studies in non-transplant populations, it would appear that transplant 
patients could similarly benefit from both inpatient and outpatient cognitive 
rehabilitation following delirium recovery in order to optimize long-term outcomes 
and maximize quality of life following transplantation.
As patients are recovering from delirium and transitioning to cognitive rehabili-
tation, it is important to focus on the completion of the treatment for any underly-
ing condition, like sepsis, that lead to or contributed to delirium development to 
ensure optimal functional recovery.
5. Outcomes
Delirium in the postoperative setting significantly impacts outcomes. Delirium 
is a predictor of mortality in hospitalized patients [61], and mortality increases 
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with the duration of delirium [71]. The relative hazard of death is nearly four times 
greater if a patient has delirium for 3 days versus no delirium. Beyond mortality, 
delirium also impacts quality of life following recovery. Delirium has been shown 
to negatively impact long-term cognitive function [72]. A recent multicenter, 
prospective, cohort study of critically ill patients was evaluated to estimate the 
prevalence of long-term cognitive impairment after critical illness [2]. The study 
enrolled adults with respiratory failure or shock in the medical or surgical intensive 
care unit, evaluated them for in-hospital delirium, and assessed global cogni-
tive and executive function 3 and 12 months after discharge with the use of the 
Repeatable Battery for the Assessment of Neuropsychological Status. The study 
showed that one out of four patients had cognitive impairment 12 months after 
critical illness that was similar in severity to that of patients with mild Alzheimer’s 
disease. At 3 months, 40% of the patients had global cognition scores that were 
1.5 standard deviations below the population means (similar to scores for patients 
with moderate traumatic brain injury), and 26% had scores 2 standard deviations 
below the population means (similar to scores for patients with mild Alzheimer’s 
disease). Interestingly, the degree of cognitive impairment affected older and 
younger patients equally. A longer duration of delirium was independently associ-
ated with worse global cognition at 3 and 12 months (P = 0.001 and P = 0.04, 
respectively) and worse executive function at 3 and 12 months [2]. These data 
strongly support efforts to initiate cognitive rehabilitation programs for patients 
who suffer from delirium during the postoperative period to enhance functional 
outcomes.
In regards to transplant specific outcomes in patients who suffer from delir-
ium, Lescot et al. examined postoperative outcomes for patients with and with-
out delirium following liver transplant [18]. Patients who suffered from delirium 
after liver transplant had higher rates of sepsis during the intensive care unit stay 
(18 vs. 1.2%, P ≤ 0.001), longer days requiring mechanical ventilation (2 vs. 1, 
P ≤ 0.001), longer intensive care unit length of stay (9 vs. 4 days,  
P ≤ 0.001), and longer hospital length of stay (37 vs. 20 days, P ≤ 0.001). In 
addition, patients who developed delirium had increased mortality compared 
to those patients who did not suffer from delirium, both in the short-term as 
well as at 1 year following transplant (intensive care unit mortality: 10.7 vs. 
2%, P = 0.04; in-hospital mortality: 25 vs. 6%; 1 year mortality: 32 vs. 12%, 
P = 0.007) [18]. A recent prospective cohort study to evaluate postoperative 
delirium after liver transplantation showed that 45% of recipients experience 
delirium with a median duration of 5 days [8]. Furthermore, postoperative delir-
ium was associated with a four-fold increase in intensive care unit length of stay, 
a more than two-fold increase in hospital length of stay, and decreased survival 
probability at 1 year. The authors suggest that postoperative delirium should be 
considered a preventable clinical complication, and not just a predictive risk 
factor for worse outcomes in the liver transplant population [8]. Postoperative 
complications likely contribute to both increased rates of delirium and mortality, 
however, it is clear that delirium is associated with worse outcomes.
Haugen et al. recently evaluated 125,304 adult kidney transplant recipients 
between 1999 and 2015 as reported to the Organ Procurement and Transplantation 
Network and linked to Medicare claims by the US Renal Data System [9]. 
International Classification of Diseases 9 codes for delirium were identified from 
inpatient claims throughout the entire set of initial kidney transplant hospitaliza-
tions. Haugen and colleagues showed that delirium in kidney transplant recipients 
significantly associates with patient survival, with an approximately 40% mortality 
at 5 years for patients who developed delirium post transplant compared to 10% 
mortality for patients who did not suffer from delirium [9].
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6. Summary
Delirium is a common clinical diagnosis in the solid organ transplant population. 
Delirium is under diagnosed, yet the recent appreciation of its impact on cognitive 
recovery indicates it is vital make efforts to mitigate its development and recognize 
it in a timely fashion to optimize transplant outcomes. Delirium has been shown 
to be associated with a longer length of stay, increased medical costs, increased 
morbidity/mortality and decreased cognitive function following hospital discharge. 
Non-pharmacologic preventive strategies, routine delirium screening, and per-
forming a comprehensive evaluation for an underlying medical cause of delirium 
with prompt treatment are the cornerstones of delirium management. With a 
better understanding of the negative impact on both short and long term outcomes 
associated with delirium in the transplant population, a focused, multidisciplinary 
approach to delirium prevention and management strategies to decrease the preva-
lence and minimize duration of delirium is paramount in transplant recipients. 
Delirium should no longer be viewed as an unavoidable clinical complication in 
transplant patients. Instead, proactive measures for cognitive prehabilitation in high 
risk transplant candidates, together with the use of clinical prevention bundles and 
post-delirium rehabilitation programs are key components of maximizing patient 
survival and functional outcomes following solid organ transplantation.
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